Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).

Cancer Res Treat · 2019 · PMC6333992 · PMID 29458237

Europe PMC DOI

hedged sentences

0.3000

closest p · 6.0× alpha

0.3000

boldest claim

The sentences

did not reach statistical significancep=0.30not close (p > 0.1)

For overall response rate, IX showed numerically higher response rate, however it did not reach statistical significance (44.4% vs. 33.3%, p=0.30).

also in 111,027 other papers

failed to reach statistical significancep=0.30not close (p > 0.1)

Objective response rate was numerically higher in the combination arm, though it failed to reach statistical significance (44.4% vs. 33.3%, p=0.30).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.